Bone Cancer Treatment in India and UAE | Complete Patient Guide

• CONFIRMED CANDIDATES:

• Patients with biopsy-confirmed primary bone malignancy (osteosarcoma, Ewing sarcoma, chondrosarcoma, giant cell tumor of bone — malignant variant, undifferentiated pleomorphic sarcoma of bone)

• Patients with localised or oligometastatic disease amenable to curative-intent treatment

• Patients requiring restaging or second-opinion review of existing pathology at a high-volume sarcoma center

• Patients with spinal or pelvic bone tumors requiring en-bloc resection and reconstruction with navigation-assisted or robotic surgery

• Patients with pathological fractures requiring surgical stabilization concurrent with oncological management

• Patients relapsing after first-line therapy who are candidates for ifosfamide/etoposide salvage chemotherapy or clinical trial enrollment

• REQUIRED PRE-TREATMENT DIAGNOSTICS (patients should bring or arrange prior to arrival):

• MRI of the primary tumor with contrast (whole-bone imaging to assess skip lesions)

• CT chest with contrast (pulmonary metastasis screening — the lungs are the predominant metastatic site for osteosarcoma)

• FDG PET-CT scan (metabolic staging and assessment of polyostotic involvement)

• Core needle or open surgical biopsy with full histopathological report including IHC markers (SATB2 for osteosarcoma, CD99/NKX2.2 for Ewing sarcoma)

• Bone marrow biopsy (mandatory for Ewing sarcoma staging)

• Bone scintigraphy (Tc-99m) for skeletal mapping

• ECHO / MUGA scan (baseline cardiac function — mandatory before anthracycline-based chemotherapy; ejection fraction must be ≥55%)

• Full blood count, comprehensive metabolic panel, LFTs, RFTs, LDH (elevated LDH is an independent adverse prognostic marker in osteosarcoma)

• Audiometry (baseline before cisplatin administration — ototoxicity monitoring)

• Fertility preservation counseling and gamete banking (strongly recommended for adolescents and young adults before gonadotoxic chemotherapy)

• RELATIVE CONTRAINDICATIONS / EXCLUSION CRITERIA:

• ECOG performance status ≥3 (severely limited functional capacity) — systemic chemotherapy may be poorly tolerated; palliative-intent management discussed

• Ejection fraction <40% — anthracycline-based protocols require cardiac optimization first

• Active uncontrolled infection or sepsis

• Widely metastatic disease with estimated survival <3 months — goals of care discussion warranted; palliative radiation or surgery for pain/fracture prevention may still be appropriate

• Uncontrolled bleeding diathesis (platelet count <50,000) without corrective measures

SURGICAL APPROACHES:

1. Limb-Salvage Surgery (Limb-Sparing Resection with Reconstruction) — the preferred surgical strategy for over 85% of extremity bone sarcomas at modern high-volume centers. The procedure involves en-bloc resection of the tumor with wide oncological margins (confirmed by intraoperative frozen-section analysis), followed by skeletal reconstruction using one of several strategies: (a) Endoprosthetic replacement with modular tumor megaprostheses (e.g., Compress implant system, MUTARS, or Stryker GMRS systems at the distal femur/proximal tibia/proximal humerus); (b) Osteoarticular allograft reconstruction; (c) Allograft-prosthesis composite (APC) for metaphyseal resections; (d) Vascularized fibular autograft — particularly for intercalary defects and in pediatric patients where growth preservation is a concern; (e) Rotationplasty (Van Nes procedure) — a functionally superior alternative to above-knee amputation in selected young patients with distal femur tumors, converting the ankle joint into a functional knee joint.

2. Computer-Navigated and Robotic-Assisted Resection — high-volume sarcoma centers in India and the UAE now deploy intraoperative 3D navigation systems (Stryker Navigation, Brainlab) and robotic arms (MAKO robotic system) to execute preoperatively planned osteotomy cuts with sub-millimeter accuracy. This technology is particularly critical for pelvic and sacral resections where anatomical complexity makes adequate margin attainment challenging by conventional means.

3. Amputation — reserved for cases where limb salvage is oncologically unsafe (major neurovascular encasement, extensive soft tissue contamination post-pathological fracture, failed prior limb-salvage reconstruction, or patient preference). Modern myodesis techniques and early prosthetic fitting optimize functional outcomes.

4. Curettage with Adjuvants — for low-grade tumors and giant cell tumors of bone: intralesional curettage followed by high-speed burring, phenol or argon beam coagulation of cavity walls, bone grafting or cement (PMMA) fill, and internal fixation.

5. Spinal and Pelvic Resections — technically demanding procedures requiring multidisciplinary surgical teams (orthopedic oncology, vascular surgery, colorectal/urological surgery, neurosurgery). Total sacrectomy with spinopelvic reconstruction and hemipelvectomy (internal or external) are performed at specialized centers.

SYSTEMIC THERAPY:

1. MAP Protocol (Methotrexate, Adriamycin/Doxorubicin, Cisplatin) — standard neoadjuvant and adjuvant chemotherapy backbone for osteosarcoma. High-dose methotrexate (12 g/m²) requires leucovorin rescue and intensive hydration/monitoring.

2. VDC/IE (Vincristine-Doxorubicin-Cyclophosphamide alternating with Ifosfamide-Etoposide) — standard for Ewing sarcoma per COG AEWS protocols.

3. Mifamurtide (MTP-PE, Mepact) — an immunomodulatory macrophage activator added to MAP chemotherapy in non-metastatic osteosarcoma (EMA-approved); improves 6-year overall survival by approximately 8%.

4. Denosumab (RANK-L inhibitor) — first-line systemic therapy for unresectable or recurrent giant cell tumor of bone; also used as neoadjuvant to downsize lesions prior to surgery.

5. Salvage/Second-Line Regimens for Relapsed Disease — Gemcitabine-Docetaxel, Ifosfamide-Etoposide, Regorafenib (TKI targeting VEGFR/PDGFR/FGFR), Cabozantinib, Pazopanib, and Sorafenib have demonstrated activity in refractory sarcomas.

6. Targeted Therapy for Specific Molecular Subtypes — CDK4/6 inhibitors (palbociclib) in CDK4-amplified osteosarcoma; NTRK inhibitors (larotrectinib, entrectinib) for NTRK fusion-positive bone sarcomas identified via next-generation sequencing (NGS).

RADIATION THERAPY:

1. Intensity-Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT) — for Ewing sarcoma (which is highly radiosensitive) as definitive local control when surgery is not feasible, or as adjuvant therapy post-resection with positive margins.

2. Stereotactic Body Radiation Therapy (SBRT) / Stereotactic Radiosurgery (SRS) — for oligometastatic bone lesions and spinal cord compression, delivering ablative doses (e.g., 24 Gy in 1–3 fractions) with millimeter precision while sparing adjacent neural structures.

3. Proton Beam Therapy — available at select centers; particularly advantageous for skull base and spinal chordomas and chondrosarcomas, and for pediatric cases where minimizing scattered radiation dose to growth plates and developing organs is paramount.

4. Radiofrequency Ablation (RFA) and Cryoablation — image-guided percutaneous techniques for palliation of painful bone metastases or for local control of small, surgically inaccessible lesions.

INTERVENTIONAL / SUPPORTIVE:

• Intra-arterial chemotherapy / isolated limb perfusion with melphalan — investigational in selected centers

• Zoledronic acid / bisphosphonate therapy for bone-metastatic disease pain and fracture risk reduction

• Cement augmentation (cementoplasty/vertebroplasty) for painful osteolytic lesions

• Intramedullary nailing / percutaneous screw fixation for impending or completed pathological fractures

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–2 before travel):

• Patient submits imaging, pathology reports, surgical history, and blood work to GAF Healthcare's oncology coordination team

• GAF Healthcare's medical team conducts remote case review with the receiving sarcoma multidisciplinary team (MDT) — comprising orthopedic oncologist, medical oncologist, radiation oncologist, pathologist, and radiologist

• Written treatment plan, cost estimate, and fit-to-travel clearance letter provided

• E-Medical Visa application for India initiated (typically 48–72 hour processing); UAE tourist or medical visa assistance coordinated in parallel

• Pre-travel cardiac, pulmonary, and renal baseline investigations completed at home and shared digitally

PHASE 2 — ARRIVAL & MULTIDISCIPLINARY EVALUATION (Days 1–3 in country):

• Airport pickup by GAF Healthcare's dedicated patient coordinator

• Check-in to hospital-adjacent accommodation or hospital admission suite

• Day 1–2: Comprehensive restaging workup: repeat MRI (if prior imaging >4 weeks old), CT chest, PET-CT if not recently performed, ECHO, audiometry, CBC, CMP, LDH, alkaline phosphatase, coagulation screen

• Day 2–3: Formal MDT tumor board presentation and finalization of surgical and systemic treatment plan; second-opinion pathology review of biopsy specimens by institutional sarcoma pathologist

• Patient and family education session with oncology nurse specialist and physiotherapist; fertility preservation consultation if indicated

• Pre-operative anesthetic assessment, nutritional status evaluation (NRS-2002 or MUST score), and blood banking/autologous donation if eligible

PHASE 3 — NEOADJUVANT CHEMOTHERAPY (Weeks 2–10, if applicable):

• Typically 2–3 cycles of MAP (osteosarcoma) or 2–4 cycles of VDC (Ewing sarcoma) administered as inpatient or day-case infusions

• Monitoring: weekly CBC, fortnightly renal function, methotrexate serum levels post-infusion (targeting level <0.1 µmol/L at 72 hours before leucovorin cessation)

• MRI reassessment after Cycle 2 to evaluate tumor response; PET-CT for metabolic response

• Nutritional support, GCSF (granulocyte colony-stimulating factor) for febrile neutropenia prophylaxis, antiemetics, and symptom management throughout

PHASE 4 — DEFINITIVE SURGERY (Day of procedure; typically 10–14 weeks into protocol if neoadjuvant therapy given first):

• General or spinal-epidural combined anesthesia; intraoperative neuromonitoring for spinal/pelvic cases

• Intraoperative navigation activated; planned osteotomy levels confirmed against preoperative MRI

• En-bloc tumor resection with continuous frozen-section margin analysis; specimen sent for formal histopathology including necrosis grading (Huvos grading for osteosarcoma: Grade III–IV, ≥90% necrosis = good responder)

• Reconstruction performed per preoperative plan (megaprosthesis, allograft, or composite)

• Wound closure with or without soft tissue flap coverage; surgical drain placement

• Blood transfusion managed with cell salvage where oncologically appropriate

• Procedure duration: 3–8 hours depending on complexity

PHASE 5 — IMMEDIATE POST-OPERATIVE HOSPITAL STAY (Days 1–14 post-surgery):

• Days 1–2: ICU or high-dependency monitoring; IV analgesia (PCA morphine or epidural), DVT prophylaxis (LMWH initiated 24–48 hours post-op unless otherwise contraindicated), limb elevation, neuro-vascular checks every 2 hours

• Day 3 onwards: Transfer to orthopedic oncology ward; wound inspection, drain output monitoring, oral analgesia transition

• Day 3–5: Physiotherapist-supervised active and passive range-of-motion exercises; weight-bearing protocol initiated per implant type (partial weight-bearing typically commences Day 3–5 for distal femur megaprosthesis)

• Day 7: Suture/staple line assessment; final histopathology report reviewed — margin status and necrosis grade discussed with patient and family

• Day 10–14: Hospital discharge if wound is healing primarily, patient is independently mobile with gait aids, pain is controlled on oral medication, and no fever or evidence of infection

• Blood parameters stable: Hb ≥8 g/dL, platelet count recovering, renal function within acceptable range for resumption of chemotherapy

PHASE 6 — ADJUVANT CHEMOTHERAPY (Weeks 4–24 post-surgery, ongoing in-country or repatriated):

• Typically 4–6 further cycles; planned duration 6 months total from induction

• Cycles may be initiated in India/UAE and continued at home under GAF Healthcare's telemedicine bridge — written protocol shared with home oncologist

• ECHO repeated after Cycle 4 (cumulative doxorubicin cardiotoxicity monitoring)

• Audiometric assessment after each cisplatin cycle

PHASE 7 — REHABILITATION & DISCHARGE MILESTONES (Weeks 2–10 post-surgery):

• Week 2–4: Supervised outpatient physiotherapy; progressive strengthening, gait retraining, and edema management

• Week 6: Repeat X-ray of operative site; assessment of implant seating and bone healing

• Week 6–8: Independent ambulation achieved with or without walking aid; ascending/descending stairs cleared

• FIT-TO-FLY CRITERIA MET at approximately Week 6–10: wound fully healed, DVT risk mitigated (prophylactic LMWH prescribed for the flight if >4 hours), oxygen saturation adequate, pain manageable without parenteral medications, and medical oncology chemotherapy schedule established

• Discharge documentation package: operative report, implant certificate, histopathology, chemotherapy protocol, physiotherapy program, follow-up schedule (3-monthly for first 2 years: CT chest + local MRI)

PHASE 8 — LONG-TERM FOLLOW-UP (Years 1–5):

• 3-monthly surveillance imaging for first 2 years (CT chest for pulmonary metastasis, MRI local site)

• Annual bone density (DXA) assessment — chemotherapy and disuse induce secondary osteoporosis

• Prosthetic implant review at 1 year, 3 years, 5 years — assessment for aseptic loosening, periprosthetic fracture, or mechanical failure

• Telemedicine follow-up with GAF Healthcare's coordinating oncologist bridges international patients with their treating team in India or the UAE